Home > Boards > US Listed > Biotechs > Clovis Oncology, Inc. (CLVS)

Great call !! My Jan 15th $35 call

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Bylerzone Member Profile
 
Followed By 48
Posts 891
Boards Moderated 0
Alias Born 04/03/14
160x600 placeholder
Top 10 deletions to the MSCI US Small Cap 1750 Index during semiannual shuffle Seeking Alpha - 11/12/2021 3:07:11 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/3/2021 4:47:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/3/2021 4:20:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/3/2021 4:20:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/3/2021 4:17:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/3/2021 4:17:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/3/2021 4:16:41 PM
Clovis reports slight decrease in Q3 Rubraca sales due to pandemic; shares down 7% Seeking Alpha - 11/3/2021 9:18:22 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/3/2021 8:07:39 AM
Clovis Oncology EPS misses by $0.08, misses on revenue Seeking Alpha - 11/3/2021 8:04:22 AM
Clovis Oncology Announces Third Quarter 2021 Operating Results Business Wire - 11/3/2021 8:00:00 AM
Clovis Oncology Q3 2021 Earnings Preview Seeking Alpha - 11/2/2021 11:32:16 AM
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3 Business Wire - 10/20/2021 8:00:00 AM
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement Business Wire - 10/19/2021 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/12/2021 9:30:43 AM
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286 Business Wire - 10/7/2021 9:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 10/5/2021 4:31:58 PM
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program Business Wire - 9/20/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/3/2021 4:17:04 PM
Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland Business Wire - 8/24/2021 2:00:00 AM
Clovis Oncology gibt die Verfügbarkeit und Erstattung von Rubraca® (Rucaparib) Tabletten für Frauen mit rezidiviertem Eierstockkrebs in der Schweiz bekannt Business Wire - 8/24/2021 2:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/16/2021 4:34:32 PM
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program Business Wire - 8/16/2021 4:21:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2021 1:02:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2021 8:06:35 AM
Bylerzone   Wednesday, 12/02/15 12:09:37 PM
Re: l2 hunter post# 87
Post # of 687 
Great call !! My Jan 15th $35 call is amazing!! This chart is gonna explode! Great call at the bottom there L2!!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences